Product Description
CM5480 acts by selectively and potently inhibiting CRAC channels, of which Orai1 is the pore-forming subunit, to control the entry of calcium ions into cells. This mechanism is the same as CalciMedica's lead drug candidate, Auxora™, which is currently in clinical development for acute kidney injury (AKI) and acute pancreatitis. (Sourced from: https://ir.calcimedica.com/news-releases/news-release-details/calcimedica-announces-publication-jci-insight-preclinical-data)
Mechanisms of Action: CRAC Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CalciMedica, Inc.
Company Location: Western America
Company Founding Year: 2007
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Pancreatitis, Acute|Arthritis, Rheumatoid
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|